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Background: There is a paucity of literature about the beneﬁts of bone-targeted agents for breast cancer
patients with bone metastases treated in the non-trial setting. We explored the incidence, consequences,
and treatment of bone metastases at a single cancer centre.
Methods: Electronic records of metastatic breast cancer patients were reviewed and pertinent informa-
tion was extracted.
Results: Of 264 metastatic breast cancer patients, 195 (73%) developed bone metastases. Of these patients,
176 were eligible for analysis. Median age at bone metastases diagnosis was 56.9 years (IQR 48–67) and
initial presentation of bone metastases included asymptomatic radiological ﬁndings (58%), bone pain (40%),
or a SRE (12.5%). Most patients (88%) received a bone-targeted agent, starting a median of 1.5 months (IQR
0.8–3.30) after bone metastasis diagnosis. 62% of patients had Z1 SRE. The median time from bone
metastasis diagnosis to ﬁrst SRE was 1.8 months (IQR 0.20–8.43 months). Median number of SREs per
patient was 1.5 (IQR 0–3). Overall, 26.8% of all SREs were clinically asymptomatic. Within the entire cohort,
51% required opioids and 20% were hospitalized due to either an SRE or bone pain.
Conclusions: Despite extensive use of bone-targeted agents, the incidence of SREs remains high. Nearly half
of SREs occur prior to starting a bone-targeted agent. Use of opioids and hospitalizations secondary to bone
metastases remain common. More effective treatment options are clearly needed.
& 2013 Elsevier GmbH. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Despite advances in the treatment of early stage breast cancer,
bone remains the most common site of distant metastasis [1]. The
consequences of bone metastases include reduced survival, mor-
bidity, pain and reduced quality of life [2]. While the care of these
patients is multidisciplinary, possibly the most attention in recent
decades has been given to the role of bone-targeted agents (BTAs)
such as bisphosphonates and denosumab. Clinical trials of BTAs
have shown statistically signiﬁcant reductions in the incidence of,
and time to, skeletal related events (SREs) (deﬁned as need for
surgery or radiotherapy to bone, pathological fractures, spinal cord
compression, hypercalcemia) and reduced bone pain in patients
with bone metastases from breast cancer [3–7] (Table 1). As a
result of these trials, BTAs have become a standard of care, with
treatment starting at the time of bone metastasis diagnosis until
evidence of a substantial decrease in performance status [8,9].
With the widespread use of BTAs there is a growing body of
data that suggests that their beneﬁts in routine clinical practice are
more modest than that observed in randomised trials [10–14]
(Table 2). We therefore decided to evaluate the incidence, con-
sequences, and management of bone metastases in an unselected
cohort of breast cancer patients at a large Canadian cancer centre.
In addition, we assessed less commonly reported clinical outcomes
of importance to patients and the health care system, such as the
use of opioids and the need for hospitalization due to skeletal
complications.
2. Methods
2.1. Data collection
Registry information was available for all patients seen with a
diagnosis of breast cancer at The Ottawa Hospital Cancer Center
between January 2008 and June 2012. Electronic charts were
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screened manually (IK, PM, TN) to identify eligible patients.
Eligibility criteria included: radiologically and/or pathologically
conﬁrmed bone metastases, breast cancer as the only diagnosed
malignancy, and complete electronic chart data (i.e., radiologic
imaging, serum calcium levels, reports of radiation/surgical proce-
dures, and clinic dictations). Data collected included demographic
Table 1
Overview of SREs on BTA in randomised trials.
Reference Study Patients with
bone disease
only (%)
Radiologic screening Outcomes on BTAs Overall survival
Hortobagyi [3] Pamidronate 90 mg
IV vs. placebo
62 (pam)
60 (placebo)
Radiographic surveys of the
skeleton were performed before
entry into the study and after
3, 6, and 12 cycles of treatment
Median time to SRE—13 months
Proportion of SREs—46%
14.8 vs. 14.2
months, no
difference
Theriault [4] Pamidronate 90 mg
IV vs. placebo
66 (pam)
72 (placebo)
Radiologic bone survey within
1 month before entry and then
at cycle 3, 6, 12, 18, 24 or at last
visit if came off prematurely
Delay in 1st SRE-10.4 months
SRE rate—56%
23.2 vs. 23.5
months, p¼0.685
Conte [26] Pamidronate 45 mg
IV vs. control
55 (overall) Bone survey on study entry ,
then at 3 and 6 month
Delay in 1st SRE—13.1 months pam-592 control—
642 days, no
difference
Hultborn [33] Pamidronate 60 mg
vs. control
54 (pam)
57 (placebo
Bone scan and directed
X-ray at study entry, then
every 6 months
SRE-free survival 11.8 months n/a
Body [6] Ibandronate 2 mg or
6 mg vs. placebo
66 (6 mg)
69 (2 mg)
67 (placebo)
Not speciﬁed SMR-1.19 for 6 mg median time
to 1st SRE 50 weeks
8 patients died in
IBA, 15 in placebo
Kohno [5] Zoledronic acid 4 mg
IV vs. placebo
Not speciﬁed Radiologic bone survey on study
entry, then at 3, 6, 9, 13 months,
bone scan on study entry and at
6 and 13 months
Proportion of patients with
SREs—30% SRE rate ratio at
1 year—0.61Time to 1st SRE
not reached
n/a
Rosen [21] Zoledronic acid 4 mg
IV vs. pamidronate
90 mg IV
Not speciﬁed Radiologic bone survey on study
entry, then at 3, 6, 9, 13 months,
bone scan on study entry and at
6 and 13 months
Time to 1st SRE Zoledronic
acid—356 days
Pam—376 days SMR Zoledronic
acid—1.04 Pam—1.39
More than 2 years,
no difference
between arms
Stopek [28] Zoledronic acid 4 mg
IV vs. denosumab
120 mg SC
Not speciﬁed Skeletal surveys or any of
radiological assessment (X-ray, CT ,
MRI) every 12 weeks
Time to 1st SRE Zoledronic acid—26.4 months
Denosumab-not reached SMR Zoledronic acid—
0.58 Denosumab—0.45
No difference
between
treatment groups
Table 2
Overview of retrospective data of SREs on bone-targeted agents.
Reference Study N Proportion of
patients
with only bone
disease (%)
Frequency of
radiologic
assessment
Outcomes Overall survival
Trinkaus [11] Retrospective study 87 35 N/a Time to 1st on pamidronate
SRE—267 days
N/a
SREs on pamidronate Proportion of patients with
SRE—38%
Liauw [14] Retrospective study 110 58 N/a Time to 1st SRE—365 days 818 Days from start of
bisphosphonatesSREs on IV bisphosphonates Proportion of patients with
SREs—30%
Murphy [34] Retrospective study 62 N/a N/a Proportion of patients with
SREs—zoledronic acid—75%
Pam—62%
N/a
SREs on IV bisphosphonates
Young [12] Retrospective study 11 7.2 at diagnosis N/a Proportion of patients with
SREs—42.3%
1.9–1.6 years, median 1.5 years
SREs on zoledronic acid
Crawford [35] Retrospective study 181 Proportion of patients with
SREs—30%SREs on IV bisphosphonates
Ding [13] Retrospective study 37 N/a Proportion of patients with
SREs—34.8%
Median 64 months
(range 57–70)SREs on bisphosphonates
181 patients
Current study Retrospective study 177 20.4 Q 3–5 months in
54%
of patients
Time to 1st SRE on BTA—8.3
months
Proportion of patients with SRE on
BTA—48%
Median 40.0 months
(IQR 22.3–93.3 months)Patients diagnosed with bone
metastases
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information, primary tumor features, time from primary diagnosis
to development of bone metastases, presentation and distribution
of bone metastases, presence of non-bone metastatic disease,
incidence of SREs (deﬁned as; pathologic fractures, need for
radiation or surgical interventions to bone, spinal cord compres-
sion, and hypercalcemia of malignancy), time to SRE from the ﬁrst
date of BTA treatment, opioid treatment for bone pain control, and
hospitalizations secondary to bone complications (SREs and pain
control).
In order to assess the proportion of patients with ﬁrst SRE prior
to and after initiation of a BTA, SREs were considered to have
occurred before BTA treatment if the therapy was administered as
a consequence of the development of an SRE or if the SRE had
occurred within 1 month of starting the BTA [11,14]. Treatment
data collected included time of initiation of BTA treatment from
the time of diagnosis of bone metastases, type of BTA, reasons
for discontinuation of BTA treatment, and, when applicable, why
BTAs were not commenced. Information on current and previous
chemotherapy and hormonal treatments was also collected.
The study was approved by the local institutional Research
Ethics Board.
2.2. Statistical methods
Patient demographic variables were summarized using proportions
for dichotomous measures, and means (with standard deviations) or
medians (with interquartile range) for continuous measures. Binary
outcomes of interest (including types of BTA administered, reasons for
discontinuation/avoidance of BTAs, administration of multiple BTAs,
the occurrence of SREs before/after BTA administration and individual
types of SREs observed) were summarized using proportions and
associated 95% conﬁdence intervals. Kaplan–Meier analyses were
performed to estimate the median time and associated interquartile
range for all time-to-event outcome measures of interest; where
clinical subgroups of patients were of interest, log rank tests were
performed to make these comparisons. A multivariable logistic
regression analysis to explore predictive variables of SRE occurrence
was also conducted and considered six covariates: age at time of
diagnosis (tertiles deﬁned by; o50 years, 50–60 years, and 460
years), hormone receptor status (HER2 positive vs. ER or PR positive
and HER2 negative, vs. triple negative), number of bone metastases
(0–4 vs. 5 or more), duration of bone metastases (o2 years vs. 2 years
or more), timing of BTA initiation from bone metastasis diagnosis (r3
months vs. 43 months vs. no BTA use), and timing of BTA admin-
istration (before any SREs vs. other). All data analyses were performed
using SAS software (version 9.2, Cary, North Carolina).
3. Results
3.1. Overview of cohort characteristics
Of 2096 charts screened, 264 patients had metastatic disease. Of
these patients, 195/264 (73%) had bone metastases. Nineteen of these
195 patients were excluded from further analysis, due to diagnosis of
second primary tumor (n¼11) and loss to follow up (n¼8). Data from
176 patients were therefore included for further analysis. Median
duration of patient follow up, as measured from time of primary
diagnosis to date of last visit, was 51.6 months (0.47–472.1 months). At
the time of study analysis 99/176 (56%) patients were dead.
Baseline characteristics of the patients are summarized in
Table 3. Median age was 56.9 years (IQR 47.5–67.0), 85.2% were
hormone receptor positive, 18.8% were HER2 positive, and 5.7%
were triple negative. At the time of initial breast cancer diagnosis,
21 (11.9%) were stage I, 38 (21.6%) stage II, 39 (22.2%) stage III and
74 (42.1%) stage IV. Stage was unknown for 3 (1.7%) patients, and 1
(0.6%) patient had ductal carcinoma in situ at primary diagnosis. In
the course of their disease, from diagnosis of metastatic disease to
last follow up or death, 60 (34.1%) also had soft tissue involvement,
123 (69.8%) visceral metastases, and 39 (22.5%) brain metastases.
Bone only metastases throughout the course of disease until last
follow up or death were observed in 36 women (20.4%). Median
time from primary breast cancer diagnosis to development of bone
metastases was 23.1 months (IQR 0.85–71.2 months). Of the
patients analyzed, 31% presented with bone metastases at initial
breast cancer diagnosis. The most frequent locations of bone
metastases were the thoracic spine (83.5%) and lumbar spine
(78.4%) (Fig. 1). Initial diagnosis of bone metastases was most
commonly a result of asymptomatic radiological ﬁndings (58%),
followed by pain (40.3%), and an SRE (12.5%). Most patients who
presented with an SRE also had bone pain at the same time (86%).
For management of their metastatic disease, the majority
of patients received hormonal therapy (76.7%) or chemotherapy
(67.6%). Over the study period, patients had a median 1 line
of endocrine therapy (range 0–5) and 1 line of chemotherapy
(range 0–7). Radiologic assessments of metastatic disease (includ-
ing one of following: bone scan, X-ray, CT scan, MRI) were
performed every 3–5 months in 54% of patients.
3.2. Bone-targeted agent use
Overall, 88% percent of patients received a BTA. The most
commonly used BTA across all lines of therapy was pamidronate
(85.8%) as standard of care and funding across most of Canada.
This was followed by zoledronic acid (13.1%), clodronate (8.0%) and
denosumab (2.8%). Median time from diagnosis of bone metas-
tases to BTA initiation was 1.5 months (IQR 0.8–3.30) and the
median time on BTA therapy was 22.0 months (IQR 5.2–37.1).
Treatment was eventually discontinued in 95 patients (61.2%) due
to: deterioration and/or death (n¼64, 41.2%), progressive bone
metastases (n¼2, 1.2%), side effects (n¼8, 5.1%), progressive
disease (n¼2, 1.2%), patient's (n¼2, 1.2%) and physician's prefer-
ence (n¼3, 1.9%). Treatment was discontinued in one patient due
to contraindication and reason was unknown in 15 patients (9.6%).
With respect to side effects as the reason for drug discontinuation,
pamidronate was discontinued due to elevated creatinine levels (n¼7)
and chronic heart failure exacerbation (n¼1). Three patients discon-
tinued clodronate due to gastro-intestinal intolerance and one patient
for non-speciﬁed poor tolerability. One patient (0.6%) was diagnosed
with osteonecrosis of the jaw (after 3 years of pamidronate).
Thirty six patients (23.2%) were switched to another BTA, 26 of
them due to progression of bone metastases on prior BTA, 5 due to
side effects of prior BTA, 5 based on physician's preference and
1 due to lack of funding. The most commonly prescribed agent in
the second line setting was zoledronic acid (57.1%). In those 21
patients who never started a BTA, the reasons included: physician
choice (18/176¼10.2%) and patient refusal (3/176¼1.7%).
3.3. Consequences of bone metastases
A Kaplan–Meier curve for survival of patients with bone
metastases is shown in Fig. 2. The median overall survival from
diagnosis of metastatic disease was 40.0 months (IQR 22.3–93.3
months). 62% of patients diagnosed with bone metastases had Z1
SRE, with a median time from BM diagnosis to ﬁrst SRE of
1.8 months (IQR 0.20–8.43 months). Among 155 patients receiving
BTAs, 50 (32.4%) never experienced an SRE, 75 patients (48.4%)
had their ﬁrst SRE prior to initiation of BTA treatment, and 29
(18.8%) had their ﬁrst SRE after BTA treatment initiation (Fig. 3).
Over the entire course of the study, 74/155 patients (48%)
experienced at least one new SRE after initiation of BTA.
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The median time from the ﬁrst dose of BTA to the ﬁrst SRE
following the initiation of treatment was 8.3 months (IQR 0.9–29.7
months). Of 435 identiﬁed SREs, the most frequent were: radiotherapy
(68.1%), fractures (17.2%), surgery (6.2%), hypercalcemia (4.8%) and
spinal cord compression (3.7%). The most common sites of SRE
occurrence were the thoracic (25.4%) and lumbar spine (16.2%).
Table 3
Baseline patient and disease characteristics.
Characteristic Patients on BTAs (n¼155) Patients not on BTAs (n¼21) All patients (n¼176)
Age at primary breast cancer, years (mean, SD) 56.2 61.8 56.9 (13.3)
BC stage at primary diagnosis
I 20 (12.9%) 1 (4.7%) 21 (11.9%)
II 32 (20.6%) 6 (28.5%) 38 (21.6%)
III 33 (21.2%) 6 (28.5%) 39 (22.2%)
IV 67 (43.2%) 7 (33.3%) 74 (42.1%)
Unknown 2 (1.2%) 1 (4.7%) 3 (1.7%)
DCIS 1 (0.6%) 0 (0%) 1 (0.6%)
Subtype of primary BC
Invasive ductal 122(78.7%) 17 (81%) 139 (79%)
Invasive lobular 21 (13.5%) 2 (9.5%) 23 (13.1%)
Invasive other 10 (6.4%) 2 (9.5%) 12 (6.8%)
Missing 2 (1.2%) 0 (0%) 2 (1.1%)
Inﬂammatory breast cancer 10 (6.5%) 4 (19%) 14 (7.9%)
ER status
Negative 18 (11.6%) 7 (33.3%) 25 (14.2%)
Positive 137 (88.4%) 13 (62%) 150 (85.2%)
Unknown 0 (0%) 1 (4.7%) 1 (0.6%)
PR status
Negative 38 (24.6%) 10 (47.6%) 48 (27.3%)
Positive 116 (74.8%) 10 (47.6%) 126 (71.6%)
Unknown 1 (0.6%) 1 (4.7%) 2 (1.1%)
HER2 status
Negative 120 (77.4) 13 (61.9%) 133 (75.6%)
Positive 29 (18.7%) 4 (19%) 33 (18.8%)
Unknown 6 (3.8%) 4 (19%) 10 (5.7%)
Grade
1 14 (9%) 3 (14.2%) 17 (9.7%)
2 74 (47.7%) 5 (23.8%) 79 (44.9%)
3 36 (23.2%) 5 (23.8%) 41 (23.3%)
Unknown 31 (20%) 8 (38%) 39 (22.2%)
SD—standard deviation, BC—breast cancer, ER—estrogen receptor, PR—progesterone receptor, BTA—bone targeted agent.
Fig. 1. Bone metastases distribution.
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Overall, 26.8% of all SREs were clinically asymptomatic i.e., asympto-
matic fractures that were usually detected on radiology and the
radiotherapy was given for prevention of further fractures.
A higher proportion of patients had fractures and hypercalce-
mia and spinal cord compression as their 1st SRE prior to start of
BTAs, whereas more patients underwent surgery after BTA initia-
tion (Table 5).
3.4. Predictive factors for SREs
Of the patients who had an SRE before commencing a BTA,
62/75 (82.7%) went on to have further SREs after starting a BTA.
Contrarily, of the patients who did not have an SRE before
commencing a BTA, 25/80 (31.2%) went on to have at least one
more1 SRE (OR 10.3, 95% CI 4.8–22.1) after starting BTA.
In a multivariable analysis, there was no increased risk of an
SRE in patients aged 50–60 years (OR 0.71, 95% CI 0.31–1.62) or
460 years (OR 1.10, 95% CI 0.49–2.48) when compared to those
o50 years. Patients with bone metastases for 2 years or longer
had a higher risk to develop SREs than those who did not (OR 2.63,
95% CI 1.36–5.09). Patients with 5 or more bone metastases were
more likely to have an SRE than those with 4 or fewer (OR 2.04,
95% CI 1.02–4.10). With regard to bone only disease as risk factor
for SREs vs. bone and visceral and/or brain metastases the odd
ratio was 1.55, suggesting there may be a higher incidence of SRE
in patients with bone only disease, however, the conﬁdence
interval was wide (95% CI 0.71–3.39). There was no signiﬁcant
difference in incidence of SREs between patients with hormone
receptor positive and hormone receptor negative disease, how-
ever, number of patients was relatively small. Type of lesion
(lytic vs. sclerotic) and rate of bone turnover as determined by
collagen breakdown markers or bone formation markers were
previously reported as important predictors of SREs [10]. However,
pure lytic vs. sclerotic disease is rarely seen these days when bone-
targeted agents are so widely used. The vast majority of patients
have mixed metastases. There was no consistency in the study
around the use of plain ﬁlms for baseline lytic vs. sclerotic
assessment across all sites of bone metastases and therefore this
data was not collected. In addition, data on alkaline phosphatase
had not been collected due to lack of consistency in timing and
Fig. 2. Kaplan–Meier curve for survival of patients from time of diagnosis of bone metastases.
Fig. 3. Time to ﬁrst SRE from diagnosis of bone metastases (n=110 patients).
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laboratory of blood tests among patients that reﬂects differences
in physicians practice and is one of known limitations of
retrospective study.
Most of the patients who did not receive a BTA, had predomi-
nantly visceral (18/21¼81%) or brain metastases (6/21¼28.6%),
higher proportion of ER (33%vs.11%) and PR (47%vs.24%) negative
tumors compared to group of patients on BTAs, and remaining
three patients from this group had low burden metastatic disease
with single bone or soft tissue metastases (Table 4). In this group 6
(27%) patients experienced at least one SRE. Within the entire
cohort of patients with bone metastases, 51% required opioids to
control associated pain, and 20% were hospitalized due to an SRE
or bone pain.
4. Discussion
The impact of bone metastases from breast cancer on patients'
survival, quality of life, mobility and functional independence are
well recognized. However, despite the multidisciplinary nature of
care of these patients, in recent decades the focus of randomised
trials has been predominantly on the beneﬁts of BTAs on SREs. The
purpose of the current paper was deliberately broad and designed
to assess the consequences of the occurrence of bone metastases
in patients treated outside of the clinical trial setting. We also
wished to informally compare our ﬁndings and other retrospective
and clinical trial datasets. We also attempted to evaluate potential
predictive for identifying patients at different risk for developing
SREs [15–17].
As an overview of the cohort characteristics it is interesting
simple observation that despite advances in adjuvant therapy that
the proportion of patients with bone metastases remains the same
(70%) as originally reported over 30 years ago [1]. As with other
series, patients with bone metastases appear to have a favorable
survival with a median overall survival from diagnosis of meta-
static disease of 40.0 months (IQR 22.3–93.3 months) [13,18–20].
In our current series, most patients with bone metastases received
a BTA starting soon after being diagnosed with bone metastases
(median 1.5 months (IQR 0.8–3.30)). Patients were continued IV
bisphosphonates every 3–4 weeks in most cases until signiﬁcant
deterioration or death, as per treatment guidelines [8].
It is of note that the incidence of SREs in patients who received a
BTAs in our study was 62% with the majority of ﬁrst SRE (75/155,
48.4%) occurred either before commencing a BTA or within 1 month
of starting a BTA. The incidence of SREs prior to bone-targeted
therapy is in keeping with the literature [3,21]. This likely reﬂects
the imaging that is performed when the patient is being worked up
for her new symptoms and therefore the suspicion of bone recur-
rence is being raised. For example, in our series 40% of patients had
signiﬁcant pain at the time of diagnosis of bone metastases, and it is
therefore not surprising that palliative radiotherapy (an SRE) was
offered in order to achieve pain relief. Indeed, in our study the most
frequent SRE was radiotherapy with pain and prevention of fraction
or spinal cord compression as indication for treatment.
However, it should be noted that large proportion of patients
develop at least one SRE after BTAs initiation (74/155, 48%) appearing
to be in keeping with the results of randomised BTA trials [3–6].
Indeed, for those patients who had not had an SRE prior to commen-
cing a BTA, their risk of subsequent SREs was much lower than that
observed in patients who had had an SRE prior to starting therapy and
may therefore identify a potential lower risk patient population for
alternative treatment strategies [22–25]. It is of interest that the
majority of SRE in this study occurred within ﬁrst 3 months of starting
BTAs, similar observations have been observed before [3,4] where
differences in incidence of SREs between pamidronate and placebo
became signiﬁcant after 3–6 months of treatment. This likely reﬂects
the time needed for bone physiology to be modiﬁed to reduce SREs
such as fractures.
Table 4
Patient characteristics at time of bone metastases diagnosis.
Patient characteristic Patients on BTAs (n¼155) Patients not on BTAs (n¼21) All patients (n¼176)
Bone only metastases, n (%) 33 (21.3%) 3 (14.2%) 36 (20.4 %)
Solitary bone metastases, n (%) 8 (5.2%) 1 (4.7%) 9 (5.1%)
Metastasis sites in addition to bone
Visceral, n (%) 105 (68%) 18 (81%) 123 (69.8%)
Brain, n (%) 33 (21.3%) 6 (28.6%) 39 (22.5%)
Soft tissue and lymph nodes, n (%) 51 (33%) 9 (42.8%) 60 (34.1%)
Presentation of BM
Asymptomatic, presented at staging investigations, n (%) 86 (55.5%) 16 (76.2%) 102 (58%)
Pain, n (%) 66 (42.6%) 5 (23.8%) 71 (40.3%)
SRE, n (%) 21 (13.5%) 1 (4.7%) 22 (12.5%)
Bone metastases at breast cancer, Dx 49 (31.6%) 5 (23.8%) 24 (31%)
Number of lines of systemic treatment chemotherapy (median, minimum, maximum) 1(0–7) 1(0–4) 1 (0–7)
Number of lines of hormonal therapy (median, minimum, maximum) 1(0–5) 0 (0–4) 1 (0–5)
SRE prior to BP use, n (%) 75 N/A 75 of 154 (48.7%)
Frequency of radiologic assessment
Q 1–2 months 17 (11%) 4 (19%) 21 (11.9%)
Q 3–5 months 93 (60%) 3 (14.2%) 96 (54.5%)
Q 6–9 months 34 (21.9%) 4 (19%) 38 (21.6%)
Q 10–12 months 6 (3.8%) 3 (14.2%) 9 (5.1%)
More than 12 months 2 (1.2%) 0 (0%) 2 (1.1%)
Once 2 (1.2%) 7 (33%) 9 (5.1%)
Missing 1 (0.6%) 0 (0%) 1 (0.6%)
Table 5
Nature of 1st SRE in patients who had Z1 SRE depending on whether the ﬁrst SRE
occurred prior or after initiation of bone-targeted therapy.
SRE Prior to initiation of
BTA, n (%)
After initiation of
BTA, n (%)
No. of patients 75 of155 74 of 155
Radiotherapy to bone 63(40.6%) 69 (44.5%)
Fractures 32 (21%) 21 (13.5%)
Spinal cord compression 7 (4.5) 7 (4.5%)
Surgery to bone 9 (6%) 11 (7%)
Hypercalcemia 12 (8%) 6 (4%)
BTA¼bone targeted agent, SRE¼skeletal related event.
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In our current series, we saw that 26.8% of SREs were asympto-
matic, and thus likely found as a result of routine bone imaging.
This is of note, as most prospective trials of BTAs do not report
how SREs were identiﬁed (i.e., symptomatic vs. asymptomatic
radiologic ﬁndings). In contrast, retrospective studies (Table 2) are
mostly focused on symptomatic SREs, as reﬂected by the lower
incidence of SREs reported, generally around 30% [11–14].
A similarly low incidence of SREs was recently observed in the
ZOOM trial, where patients only underwent imaging at the
discretion of the treating physician [22]. Indeed, the proportion
of clinically signiﬁcant fractures was lower in our study (17.2%)
than in large randomised bisphosphonate trials (25–45%)
[4,21,26], while the proportion of patients receiving radiation to
bone was higher (68% vs. 10–40%). These frequencies were more in
keeping with other retrospective series [11,14].
Comparison of the beneﬁts of BTAs between real world and
clinical trial populations is important, for a number of reasons.
Firstly, the frequency of radiological investigations is likely sig-
niﬁcantly less for patients treated in routine clinical practice
compared to those entered on a clinical trial [27]. Individuals in
the randomized studies underwent skeletal imaging every 12
weeks [4,21,28], and the SREs reported in these trials thus
represents the composite of both symptomatic and asymptomatic
radiological changes. In our current series bone imaging was
performed every 3–5 months as part of systemic assessment of
metastatic disease in a 54% of patients, once in 6 months and less
frequent in 30%. 12% of patients had some imaging more fre-
quently than every 3 months, mostly as part of follow up with CT
scan for rapidly progressive visceral disease. In addition, clinical
trial patients usually have a better performance status due to
restrictive inclusion criteria; moreover, most of the patients
enrolled in BTA trials have metastatic disease conﬁned to skeleton
only (55–70%), while in our study a signiﬁcant proportion of BTA-
treated bone metastatic patients also had visceral metastases
(68%, 105/155). Again this is comparable with the most of retro-
spective trials (Table 2). Also of interest is the relatively low
incidence of reported ONJ seen in the current series 0.6% again
consistent with the literature [29].
As with other series, we have shown that multiple bone
metastases, presence bone metastases for more than two years,
and occurrence of previous SREs are associated with a risk of
further SREs [10,12,30]. Several trials have investigated predictive
factors for developing SREs among women with bone metastases
secondary to breast cancer on bisphosphonate treatment. Baseline
patients characteristics from randomized prospective trials inves-
tigating the efﬁcacy of pamidronate in this group found increased
SREs risk with presence of more than two osteolytic lesions, high
pain scores, and history of prior radiation therapy [30]. Another
retrospective analysis of a large prospective trial comparing
zoledronic acid to pamidronate in women with bone metastases
secondary to breast cancer found that age older than 60, Brief Pain
Inventory score higher than 3, prior SREs and predominant lytic
bone lesions put patients at an increased higher risk for subse-
quent SREs [10]. One retrospective study showed increased inci-
dence of SREs in patients with pre-existing osteoporosis [11].
Clearly there are limitations to the current study. These include
the single centre, retrospective nature of the study as well as its
relatively small sample size compared with the randomised data.
However, the duration of follow up is considerably longer than
these trials (Table 1).
In conclusion, despite our increased understanding of the
biology of metastatic bone disease [31,32] bone remains the most
common site of breast cancer recurrence. Despite extensive use of
BTAs the incidence of SREs remains high as does the use of opioid
analgesics and hospitalizations secondary to bone metastases.
Thus despite signiﬁcant advances in the care of these patients
there is a need for more effective treatment options and more
individualized approach for these patients.
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